Milestone Pharmaceuticals’ etripamil nasal spray meets primary endpoint of phase 3 trial in PSVT
Patients subjected to etripamil showed a statistically significant difference in time to conversion to PSVT, compared to placebo,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Oct 22
Patients subjected to etripamil showed a statistically significant difference in time to conversion to PSVT, compared to placebo,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Oct 22
Boehringer Ingelheim is seeking approval in the European Union for its IL-36R inhibitor in generalised pustular psoriasis based…
17 Oct 22
The funding will help to generate new treatments and improve the delivery of healthcare services to support experimental…
14 Oct 22
The new financing will allow Odyssey Therapeutics to advance its portfolio of precision immunomodulators and oncology medicines, supporting…
14 Oct 22
Under the partnership, both firms will evaluate new treatment approaches by combining beta blockers plus AdAlta’s CXCR4-inhibiting ibodies
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Oct 22
Tavros will receive $17.5M in an upfront payment, and up to $430.5M in milestone payments for the initial…
13 Oct 22
In this connection, the US health regulator has authorised the use of Moderna’s mRNA-1273.222 and a 10-µg booster…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 Oct 22
The strategic research collaboration will combine Illumina and AstraZeneca’s combined strengths in artificial intelligence (AI) based genome interpretation…
12 Oct 22
The FDA inspectors discovered that Lilly’s employees had not properly tracked contaminated drugs batches that were supposed to…
11 Oct 22
The drug is indicated for congestion due to fluid overload in adults with New York Heart Association Class…